Back to Search
Start Over
Targeting CD24 in Cancer Immunotherapy
- Source :
- Biomedicines, Vol 11, Iss 12, p 3159 (2023)
- Publication Year :
- 2023
- Publisher :
- MDPI AG, 2023.
-
Abstract
- Immunotherapy is a hot area in cancer treatment, and one of the keys to this therapy is the identification of the right tumour-associated or tumour-specific antigen. Cluster of differentiation 24 (CD24) is an emerging tumour-associated antigen that is commonly and highly expressed in various tumours. In addition, CD24 is associated with several cancer-related signalling pathways and closely interacts with other molecules and immune cells to influence tumour progression. Monoclonal antibodies, antibody–drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapy, and CAR-NK cell therapy are currently available for the treatment of CD24. In this review, we summarise the existing therapeutic approaches and possible future directions targeting CD24.
- Subjects :
- CD24
siglec-10
immunotherapy
Biology (General)
QH301-705.5
Subjects
Details
- Language :
- English
- ISSN :
- 22279059
- Volume :
- 11
- Issue :
- 12
- Database :
- Directory of Open Access Journals
- Journal :
- Biomedicines
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.ba67e54c531a4f07bcaa90f2a7e4341b
- Document Type :
- article
- Full Text :
- https://doi.org/10.3390/biomedicines11123159